{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:02:24Z","timestamp":1793340144044,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transthyretin amyloidosis, or ATTR, is a progressive and debilitating rare proteopathy generally manifested as either transthyretin amyloid polyneuropathy (ATTR-PN) or transthyretin amyloid cardiomyopathy (ATTR-CM). Irrespective of the clinical presentation, affected patients manage a chronic and life-threatening condition that severely impacts their quality of life. Although the primary symptoms and diagnostic criteria for ATTR are increasingly being discussed in the medical literature, due in large part by continual advances in uncovering disease pathophysiology, there exists a surprising paucity of published data on the patient journey and family experience. In order to address this disparity, two focus groups, one for ATTR-CM and one for ATTR-PN, were convened and asked to describe the diagnostic process, symptoms, and impact on their own quality of life that was experienced from these rare and typically misdiagnosed illnesses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients in both ATTR groups often underwent a long and difficult diagnostic odyssey characterized by seemingly nonspecific physical manifestations resulting in mismanagement and suboptimal care, inadequate interventions, and delays in establishing the correct diagnosis, which was integral to determining the specialized treatment they needed. Collectively, patients with ATTR-CM and patients with ATTR-PN reported a similar number of symptoms, but the type of symptoms varied. The ATTR-CM group identified intolerance to activity, inability to exercise, insomnia and fatigue as the most challenging symptoms. The ATTR-PN group identified fatigue, diarrhea\/constipation and sensory deficits as the most difficult symptoms. In general, ATTR was reported to be highly stressful for both patients and their families. Spouses of patients with ATTR-CM were often in a caregiver role and reported experiencing considerable anxiety. Patients with ATTR-PN were stressed not only by the physical consequences of their illness, but also by its effects on their parents and other relatives, as well as concerns about children and grandchildren inheriting the disease-causing mutations associated with ATTR. Despite such challenges, family members are identified as an important resource of coping, motivation, inspiration and support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Several steps can be taken to reduce the challenges and burdens of living with ATTR, including increased education for primary care physicians and specialists who unknowingly encounter ATTR, increased access to and ready availability of mental health services and support, and increased engagement with support groups and advocacy organizations. Input from patients and their representatives should guide clinical trials, increase the availability of genetic testing, and generate natural history and qualitative studies detailing patients\u2019 experience. Although each recommendation is impactful in itself, taken together they would jointly facilitate a shortened and ameliorated patient journey through more timely diagnosis and greater access to personalized medical care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-021-01706-7","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T17:48:23Z","timestamp":1612806503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2951-5086","authenticated-orcid":false,"given":"David","family":"Rintell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"Braga Mendendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Knobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Turtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Kalmykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"1706_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13169","author":"E Muchtar","year":"2020","unstructured":"Muchtar E, Dispenzieri A, Magen H, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2020. https:\/\/doi.org\/10.1111\/joim.13169.","journal-title":"J Intern Med"},{"issue":"1","key":"1706_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","volume":"324","author":"MA Gertz","year":"2020","unstructured":"Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA. 2020;324(1):79\u201389. https:\/\/doi.org\/10.1001\/jama.2020.5493.","journal-title":"JAMA"},{"issue":"13","key":"1706_CR3","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM199709253371306","volume":"337","author":"RH Falk","year":"1997","unstructured":"Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337(13):898\u2013909. https:\/\/doi.org\/10.1056\/NEJM199709253371306.","journal-title":"N Engl J Med"},{"issue":"6","key":"1706_CR4","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/msj.21352","volume":"79","author":"SC Shin","year":"2012","unstructured":"Shin SC, Robinson-Papp J. Amyloid neuropathies. Mt Sinai J Med. 2012;79(6):733\u201348. https:\/\/doi.org\/10.1002\/msj.21352.","journal-title":"Mt Sinai J Med"},{"issue":"5","key":"1706_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mus.26034","volume":"57","author":"HH Schmidt","year":"2018","unstructured":"Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829\u201337. https:\/\/doi.org\/10.1002\/mus.26034.","journal-title":"Muscle Nerve"},{"key":"1706_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09688-0","author":"D Adams","year":"2020","unstructured":"Adams D, Ando Y, Beir\u00e3o JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2020. https:\/\/doi.org\/10.1007\/s00415-019-09688-0.","journal-title":"J Neurol"},{"key":"1706_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31. https:\/\/doi.org\/10.1186\/1750-1172-8-31.","journal-title":"Orphanet J Rare Dis"},{"issue":"21","key":"1706_CR8","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66(21):2451\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2015.09.075.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"1706_CR9","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003.","journal-title":"J Am Coll Cardiol"},{"key":"1706_CR10","doi-asserted-by":"publisher","unstructured":"The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995; 41(10):1403\u20139. https:\/\/doi.org\/10.1016\/0277-9536(95)00112-k.","DOI":"10.1016\/0277-9536(95)00112-k"},{"issue":"8","key":"1706_CR11","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.cardfail.2017.07.207","volume":"23","author":"M Grogan","year":"2017","unstructured":"Grogan M, Siepen F, Carter J, et al. Estimating population-level prevelance of wild-type and variant transthyretin Amyloid cardiomyopathy. J Card Fail. 2017;23(8):S73. https:\/\/doi.org\/10.1016\/j.cardfail.2017.07.207.","journal-title":"J Card Fail"},{"issue":"1","key":"1706_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16\u201326. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038169.","journal-title":"Circulation"},{"key":"1706_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.09.025","author":"A Porcari","year":"2020","unstructured":"Porcari A, Merlo M, Rapezzi C, Sinagra G. Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery. Eur J Intern Med. 2020. https:\/\/doi.org\/10.1016\/j.ejim.2020.09.025.","journal-title":"Eur J Intern Med"},{"issue":"5","key":"1706_CR14","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/s0735-1097(00)00531-3","volume":"35","author":"CP Green","year":"2000","unstructured":"Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35(5):1245\u201355. https:\/\/doi.org\/10.1016\/s0735-1097(00)00531-3.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1706_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/dia.2005.7.497","volume":"7","author":"EJ Vinik","year":"2005","unstructured":"Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients\u2019 perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2005;7(3):497\u2013508. https:\/\/doi.org\/10.1089\/dia.2005.7.497.","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"1706_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.14797\/mdcj-8-3-3","volume":"8","author":"KR Baker","year":"2012","unstructured":"Baker KR, Rice L. The Amyloidoses: clinical features, diagnosis and treatment. Methodist Debakey Cardiovasc J. 2012;8(3):3\u20137. https:\/\/doi.org\/10.14797\/mdcj-8-3-3.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"8","key":"1706_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ejim.2013.10.007","volume":"24","author":"G Palladini","year":"2013","unstructured":"Palladini G, Merlini G. Systemic amyloidoses: what an internist should know. Eur J Intern Med. 2013;24(8):729\u201339. https:\/\/doi.org\/10.1016\/j.ejim.2013.10.007.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"1706_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13023-020-1340-x","volume":"15","author":"M In\u00eas","year":"2020","unstructured":"In\u00eas M, Coelho T, Concei\u00e7\u00e3o I, Ferreira L, de Carvalho M, Costa J. Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study. Orphanet J Rare Dis. 2020;15(1):67. https:\/\/doi.org\/10.1186\/s13023-020-1340-x.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"1706_CR19","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med"},{"issue":"3","key":"1706_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","volume":"27","author":"L Obici","year":"2020","unstructured":"Obici L, Berk JL, Gonz\u00e1lez-Duarte A, et al. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2020;27(3):153\u201362. https:\/\/doi.org\/10.1080\/13506129.2020.1730790.","journal-title":"Amyloid"},{"issue":"8","key":"1706_CR21","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/ene.14285","volume":"27","author":"TH Brannagan","year":"2020","unstructured":"Brannagan TH, Wang AK, Coelho T, et al. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. Eur J Neurol. 2020;27(8):1374\u201381. https:\/\/doi.org\/10.1111\/ene.14285.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1706_CR22","doi-asserted-by":"publisher","first-page":"E60","DOI":"10.1016\/j.crvasa.2012.11.018","volume":"55","author":"M Fikrle","year":"2013","unstructured":"Fikrle M, Palecek T, Kuchynka P, et al. Cardiac amyloidosis: a comprehensive review. Cor et Vasa. 2013;55(1):E60\u201375. https:\/\/doi.org\/10.1016\/j.crvasa.2012.11.018.","journal-title":"Cor et Vasa"},{"issue":"12","key":"1706_CR23","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cardfail.2016.10.008","volume":"22","author":"DL Brunjes","year":"2016","unstructured":"Brunjes DL, Castano A, Clemons A, Rubin J, Maurer MS. Transthyretin cardiac amyloidosis in older Americans. J Card Fail. 2016;22(12):996\u20131003. https:\/\/doi.org\/10.1016\/j.cardfail.2016.10.008.","journal-title":"J Card Fail"},{"issue":"2","key":"1706_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mus.26515","volume":"60","author":"A Yarlas","year":"2019","unstructured":"Yarlas A, Gertz MA, Dasgupta NR, et al. Burden of hereditary transthyretin amyloidosis on quality of life. Muscle Nerve. 2019;60(2):169\u201375. https:\/\/doi.org\/10.1002\/mus.26515.","journal-title":"Muscle Nerve"},{"issue":"9","key":"1706_CR25","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S0735-1097(19)31471-8","volume":"73","author":"AS Kessler","year":"2019","unstructured":"Kessler AS, Yarlas A, Lovley A, et al. Clinical outcome assessment scores for patients with transthyretin amyloidosis with or without accompanying cardiomyopathy or congestive heart failure. J Am Coll Cardiol. 2019;73(9):864. https:\/\/doi.org\/10.1016\/S0735-1097(19)31471-8.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1706_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/mus.25257","volume":"55","author":"T Coelho","year":"2017","unstructured":"Coelho T, Vinik A, Vinik EJ, Tripp T, Packman J, Grogan DR. Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2017;55(3):323\u201332. https:\/\/doi.org\/10.1002\/mus.25257.","journal-title":"Muscle Nerve"},{"key":"1706_CR27","first-page":"44","volume-title":"Qualitative data analysis: a methods sourcebook","author":"MB Miles","year":"2020","unstructured":"Miles MB, Huberman AM, Salda\u00f1a J. Qualitative data analysis: a methods sourcebook. 4th ed. Thousand Oaks: SAGE Publications; 2020. p. 44\u201399.","edition":"4"},{"issue":"2","key":"1706_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41431-019-0555-6","volume":"28","author":"M Bolz-Johnson","year":"2020","unstructured":"Bolz-Johnson M, Meek J, Hoogerbrugge N. \u201cPatient Journeys\u201d: improving care by patient involvement. Eur J Hum Genet. 2020;28(2):141\u20133. https:\/\/doi.org\/10.1038\/s41431-019-0555-6.","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"1706_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/d41573-019-00180-y","volume":"19","author":"M Haendel","year":"2020","unstructured":"Haendel M, Vasilevsky N, Unni D, et al. How many rare diseases are there? Nat Rev Drug Discov. 2020;19(2):77\u20138. https:\/\/doi.org\/10.1038\/d41573-019-00180-y.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1706_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165\u201373. https:\/\/doi.org\/10.1038\/s41431-019-0508-0.","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"1706_CR31","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.pec.2018.10.022","volume":"102","author":"MS F\u00f8nhus","year":"2019","unstructured":"F\u00f8nhus MS, Dalsb\u00f8 TK, Johansen M, Fretheim A, Skirbekk H, Flottorp S. Patient-mediated interventions to improve professional practice: a summary of a Cochrane systematic review. Patient Educ Couns. 2019;102(3):474\u201385.","journal-title":"Patient Educ Couns"},{"issue":"3","key":"1706_CR32","doi-asserted-by":"publisher","first-page":"e0174329","DOI":"10.1371\/journal.pone.0174329","volume":"12","author":"MJ Armstrong","year":"2017","unstructured":"Armstrong MJ, Mullins CD, Gronseth GS, Gagliardi AR. Recommendations for patient engagement in guideline development panels: A qualitative focus group study of guideline-na\u00efve patients. PLoS ONE. 2017;12(3):e0174329. https:\/\/doi.org\/10.1371\/journal.pone.0174329.","journal-title":"PLoS ONE"},{"issue":"1","key":"1706_CR33","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s12913-017-2630-4","volume":"17","author":"AE Sharma","year":"2017","unstructured":"Sharma AE, Knox M, Mleczko VL, Olayiwola JN. The impact of patient advisors on healthcare outcomes: a systematic revie. BMC Health Serv Res. 2017;17(1):693. https:\/\/doi.org\/10.1186\/s12913-017-2630-4.","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"1706_CR34","doi-asserted-by":"publisher","first-page":"e033353","DOI":"10.1136\/bmjopen-2019-033353","volume":"9","author":"N Uhlenbusch","year":"2019","unstructured":"Uhlenbusch N, L\u00f6we B, Depping MK. Perceived burden in dealing with different rare diseases: a qualitative focus group study. BMJ Open. 2019;9(12):e033353. https:\/\/doi.org\/10.1136\/bmjopen-2019-033353.","journal-title":"BMJ Open"},{"issue":"1","key":"1706_CR35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13023-019-1146-x","volume":"14","author":"D Stanimirovic","year":"2019","unstructured":"Stanimirovic D, Murko E, Battelino T, Groselj U. Development of a pilot rare disease registry: a focus group study of initial steps towards the establishment of a rare disease ecosystem in Slovenia. Orphanet J Rare Dis. 2019;14(1):172. https:\/\/doi.org\/10.1186\/s13023-019-1146-x.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1706_CR36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13023-018-0851-1","volume":"13","author":"K Tingley","year":"2018","unstructured":"Tingley K, Coyle D, Graham ID, et al. Using a meta-narrative literature review and focus groups with key stakeholders to identify perceived challenges and solutions for generating robust evidence on the effectiveness of treatments for rare diseases. Orphanet J Rare Dis. 2018;13(1):104. https:\/\/doi.org\/10.1186\/s13023-018-0851-1.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1706_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1046\/j.1365-2648.1998.00503.x","volume":"27","author":"E Jons\u00e8n","year":"1998","unstructured":"Jons\u00e8n E, Athlin E, Suhr O. Familial amyloidotic patients\u2019 experience of the disease and of liver transplantation. J Adv Nurs. 1998;27(1):52\u20138. https:\/\/doi.org\/10.1046\/j.1365-2648.1998.00503.x.","journal-title":"J Adv Nurs"},{"issue":"2","key":"1706_CR38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40120-018-0106-z","volume":"7","author":"M Stewart","year":"2018","unstructured":"Stewart M, Shaffer S, Murphy B, et al. Characterizing the high disease burden of transthyretin amyloidosis for patients and caregivers. Neurol Ther. 2018;7(2):349\u201364. https:\/\/doi.org\/10.1007\/s40120-018-0106-z.","journal-title":"Neurol Ther"},{"issue":"7 Suppl","key":"1706_CR39","first-page":"S107","volume":"23","author":"MA Gertz","year":"2017","unstructured":"Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(7 Suppl):S107\u201312.","journal-title":"Am J Manag Care"},{"issue":"3","key":"1706_CR40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.amjmed.2019.08.032","volume":"133","author":"M Kalluri","year":"2020","unstructured":"Kalluri M, Luppi F, Ferrara G. What patients with idiopathic pulmonary fibrosis and caregivers want: filling the gaps with patient reported outcomes and experience measures. Am J Med. 2020;133(3):281\u20139. https:\/\/doi.org\/10.1016\/j.amjmed.2019.08.032.","journal-title":"Am J Med"},{"key":"1706_CR41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.rmed.2019.06.001","volume":"155","author":"CM Sk\u00f6ld","year":"2019","unstructured":"Sk\u00f6ld CM, Arnheim-Dahlstr\u00f6m L, Bartley K, et al. Patient journey and treatment patterns in adults with IPF based on health care data in Sweden from 2001 to 2015. Respir Med. 2019;155:72\u20138. https:\/\/doi.org\/10.1016\/j.rmed.2019.06.001.","journal-title":"Respir Med"},{"key":"1706_CR42","unstructured":"Amyloidosis Research Consortium. The voice of the patient report (2016). https:\/\/arci.org\/wp-content\/uploads\/2018\/05\/Voice-of-the-Patient.pdf. Accessed 29 Oct 2020."},{"key":"1706_CR43","unstructured":"Kole A, Faurison, F. The voice of 12,000 patients: Experiences and expectations of rare disease patients on diagnosis and care in Europe. Eurodiscare-2. https:\/\/www.eurordis.org\/IMG\/pdf\/voice_12000_patients\/EURORDISCARE_FULLBOOKr.pdf. Accessed 29 Oct 2020."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01706-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-021-01706-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01706-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T18:01:11Z","timestamp":1612807271000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01706-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1706"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01706-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-48013\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-48013\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-48013\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"28 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An application for Institutional Review Board approval was made to the Western Institutional Review Board, who determined that this study was exempt from IRB approval. All participants signed a consent to participate in the focus groups.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}